Eupraxia Pharmaceuticals Inc. announces the pricing of a public offering of 12,727,273 common shares at $5.50 per share for gross proceeds of approximately $70 million. The underwriters have a 30-day option to purchase an additional 1,909,090 common shares. The Company plans to use the net proceeds for product pipeline advancement, research and development, business development, and general corporate purposes. The Offering is expected to close on September 24, 2025. Cantor and LifeSci Capital are the joint book-running managers for the Offering, with Bloom Burton as co-manager. The Offering is being made under a U.S. registration statement and Canadian short form base shelf prospectus.

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on locally delivered, extended-release products using Diffusphere™ technology. Forward-looking statements in the news release include information on the Offering, the Company’s technology, and the potential impact on drug delivery. Risks and uncertainties related to the Company’s operations, technology acceptance, regulatory approvals, clinical trials, and financial requirements are also outlined. Eupraxia emphasizes that no forward-looking statement can be guaranteed, and factors beyond those mentioned may affect actual results. Contact information for investor and media inquiries is provided.

Read more at GlobeNewswire: Eupraxia Pharmaceuticals Announces Pricing of US$70 Million